A
SLNO

AlphaQuest’s Soleno Therapeutics SLNO Stock Holding History

AlphaQuest’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,408
Closed -$111K – 1764
2025
Q4 		$111K Buy
2,408
+608
+34% +$33.3K 0.01% 1704
2025
Q3 		$122K Buy
1,800
+817
+83% +$60.6K 0.01% 1643
2025
Q2 		$82.4K Hold
983
– – 0.01% 1489
2025
Q1 		$70.2K Buy
983
+268
+37% +$13.1K 0.01% 1430
2024
Q4 		$32.1K Buy
715
+658
+1,154% +$34.1K ﹤0.01% 1371
2024
Q3 		$2.88K Sell
57
-1,965
-97% -$94.1K ﹤0.01% 1589
2024
Q2 		$82.5K Sell
2,022
-574
-22% -$24.3K 0.01% 976
2024
Q1 		$111K Buy
+2,596
New +$117K 0.02% 793

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

AlphaQuest's SLNO Position: Q1 2026 in Review

AlphaQuest sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 2,408 shares — an estimated $111K sold.

AlphaQuest first reported a position in SLNO in Q1 2024 and held it in 8 quarters. The position peaked at $122K in Q3 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • AlphaQuest reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 2,408 Soleno Therapeutics shares in Q1 2026, an estimated $111K.
  • AlphaQuest first reported a position in Soleno Therapeutics in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Soleno Therapeutics position peaked at $122K in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.